In the present study, the highest statistical differences between HER2-positiveand HER2-negative mALNs in BC patients 4 h after the administration of[99mTc]Tc-(HE)3-G3 were observed for a mALN-tobackgroundratio of 26.1 ± 15.4 (p = 0.0115, Mann– Whitneytest). The gene discussed is ERBB2; the disease is breast cancer.